CI 1021

Drug Profile

CI 1021

Alternative Names: PD 154075

Latest Information Update: 22 Feb 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Analgesics; Antiemetics; Benzofurans
  • Mechanism of Action Neurokinin 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Nausea and vomiting; Pain

Most Recent Events

  • 22 Feb 2006 No development reported - Preclinical for Pain in USA (unspecified route)
  • 19 Jun 2001 No-Development-Reported for Emesis (Unknown route)
  • 22 Mar 2001 CI 1021 is being investigated for use in Pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top